Skip to main content
Fig. 3 | Alzheimer's Research & Therapy

Fig. 3

From: A single dose of the γ-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans

Fig. 3

APL1β17. The peptide DELAPAGTGVSREAVSG, constituting fragment APL1β17 from amyloid-like protein 1 (APLP1). a Annotated MS2 spectrum. b Relative abundance of the peptide after semagacestat treatment. In the 280 mg dosage group the concentration of the peptide decreased to a minimum of 32 % at 12 h (p = 0.0018), and in the 140 mg group the minimum relative concentration was 15 % at 18 h (p = 0.078). Graphed data are medians with median absolute deviations

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193